Clinical Trial Detail

NCT ID NCT04267120
Title Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

sarcomatoid renal cell carcinoma

chromophobe renal cell carcinoma

renal cell carcinoma

papillary renal cell carcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.